ASP
MLYS icon

Adams Street Partners’s Mineralys Therapeutics MLYS Stock Holding History

Adams Street Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,129,807
Closed -$13.9M – 8
2024
Q4 		$13.9M Sell
1,129,807
-402,847
-26% -$5.27M 12.33% 3
2024
Q3 		$18.6M Sell
1,532,654
-156,058
-9% -$1.89M 10.21% 4
2024
Q2 		$19.8M Sell
1,688,712
-187,780
-10% -$2.37M 8.14% 5
2024
Q1 		$24.2M Sell
1,876,492
-425,837
-18% -$5.26M 9.62% 4
2023
Q4 		$19.8M Hold
2,302,329
– – 6.1% 6
2023
Q3 		$21.9M Sell
2,302,329
-117,172
-5% -$1.53M 7.65% 5
2023
Q2 		$41.3M Hold
2,419,501
– – 10.79% 3
2023
Q1 		$37.9M Buy
+2,419,501
New +$40.7M 11.82% 3

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adams Street Partners's MLYS Position: Q1 2025 in Review

Adams Street Partners sold out of Mineralys Therapeutics (MLYS) in Q1 2025, closing a stake of 1,129,807 shares — an estimated $13.9M sold.

Adams Street Partners first reported a position in MLYS in Q1 2023 and held it in 8 quarters. The position peaked at $41.3M in Q2 2023. 149 funds tracked by Wall St. Rank hold MLYS as of Q1 2025.

  • Adams Street Partners reported no remaining Mineralys Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Adams Street Partners sold 1,129,807 Mineralys Therapeutics shares in Q1 2025, an estimated $13.9M.
  • Adams Street Partners first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 8 quarters.
  • Adams Street Partners's Mineralys Therapeutics position peaked at $41.3M in Q2 2023.
  • 149 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2025.

Based on Adams Street Partners's 13F filing for Q1 2025, filed 14 May 2025.